Equillium (EQ) Share-based Compensation (2018 - 2026)
Equillium (EQ) posted quarterly Share-based Compensation of $930000.0 for Q1 2026, up 49.76% year-over-year from $621000.0 in Q1 2025, and up 189.68% quarter-over-quarter from -$1.0 million in Q4 2025.
Equillium (EQ) Share-based Compensation (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Share-based Compensation for 9 consecutive years, with $930000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 49.76% year-over-year to $930000.0; the TTM figure through Mar 2026 stood at $1.3 million (down 60.72% YoY), while the FY2025 annual figure was $7.7 million, up 105.33% from the prior year.
- Share-based Compensation advanced to $930000.0 in Q1 2026 per EQ's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.4 million in Q3 2025 and bottomed at -$3.7 million in Q4 2022.
- Historically, Share-based Compensation has averaged $991176.5 across 5 years, with a median of $952000.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 6505.56% — and 2025, when it plunged 226.31%.
- Equillium's Share-based Compensation stood at -$3.7 million in 2022, then surged by 128.0% to $1.0 million in 2023, then retreated by 21.51% to $821000.0 in 2024, then slumped by 226.31% to -$1.0 million in 2025, then jumped by 189.68% to $930000.0 in 2026.
- Business Quant data shows EQ's Share-based Compensation at $930000.0 in Q1 2026, -$1.0 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 13.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.90 Mn |
| Jun 30, 2026 | 13.90 Mn |
| Mar 31, 2026 | 930,000.00 |
| Mar 31, 2026 | 930,000.00 |
| Dec 31, 2025 | -1.04 Mn |
| Dec 31, 2025 | -1.04 Mn |
| Sep 30, 2025 | 8.40 Mn |
| Sep 30, 2025 | 8.40 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 621,000.00 |
| Mar 31, 2025 | 621,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 952,000.00 |
| Jun 30, 2024 | 952,000.00 |
| Mar 31, 2024 | 972,000.00 |
| Mar 31, 2024 | 972,000.00 |